jeudi 29 janvier 2015

New potential therapeutic strategy against a very aggressive infant bone cancer

Inhibition of Sirtuin1 protein may be a future treatment option for metastatic Ewing sarcoma, researchers report. Ewing's sarcoma is the second most common bone cancer and affects children and adolescents. Currently, if diagnosed in time and there is no metastasis, it can be cured in 80% of cases but between 25% and 30% of cases are diagnosed when there is already metastasized, at which low survival to 30 %.

New potential therapeutic strategy against a very aggressive infant bone cancer

Aucun commentaire:

Enregistrer un commentaire